Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A.
The University of Iowa Carver College of Medicine, Iowa City, IA, USA. steven-lentz@uiowa.edu.
S R
SR
Lentz
HEMORIO, Rio De Janeiro, Brazil.
M
M
Cerqueira
School of Medicine, University of Belgrade, University Children's Hospital, Belgrade, Serbia.
D
D
Janic
Department of Hematology/Oncology, Emory University School of Medicine, Atlanta, GA, USA.
C
C
Kempton
Novo Nordisk A/S, Soeborg, Denmark.
I
I
Matytsina
National Hemophilia Center, Chaim Sheba Medical Center, Tel Aviv University, Ramat-Gan, Israel.
M
M
Misgav
Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
J
J
Oldenburg
IHTC 'Claudio L.P. Correa', INCT do Sangue Hemocentro UNICAMP, University of Campinas, Sao Paulo, Brazil.
M
M
Ozelo
The Hemophilia Center, Oregon Health & Science University, Portland, OR, USA.
M
M
Recht
Novo Nordisk A/S, Soeborg, Denmark.
A
A
Rosholm
Clinic of Hematology, Clinical Center of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
A
A
Savic
Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan.
T
T
Suzuki
Hannover Medical School, Hannover, Germany.
A
A
Tiede
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital Policlinico, Milan, Italy.
E
E
Santagostino
D000293:Adolescent; D000328:Adult; D002675:Child, Preschool; D018450:Disease Progression; D005169:Factor VIII / Q000627:therapeutic use*; D005260:Female; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007391:International Cooperation; D008297:Male; D055815:Young Adult
C577506:recombinant factor VIII N8; D005169:Factor VIII